Single: signature enabling glioma enrollment

The Defense Health Agency (DHA) awarded Translational Genomics Research Institute (TGen) a $384,000 project grant effective September 1, 2025, through August 31, 2027, under the Military Medical Research and Development program (CFDA 12.420). The project, titled "Single: Signature Enabling Glioma Enrollment," supports research and development activities focused on glioma-related medical challenges. Based on TGen's established expertise in precision medicine and genomic analysis, the award likely involves advanced biomedical research services including genomic sequencing, molecular profiling, and computational analysis to advance understanding of glioblastoma and related neurological conditions, with potential applications to military health priorities and broader public health objectives.

The Military Medical Research and Development program supports hypothesis-driven biomedical research designed to transform healthcare for service members and the American public through innovative medical solutions. TGen's research will be conducted at its Phoenix, Arizona facility and may involve collaborative partnerships consistent with the institute's track record of leading multi-institutional research initiatives. The two-year performance period aligns with typical DHA funding timelines, which emphasize both technical merit and military relevance in addressing critical health challenges across oncology, neurology, and related medical domains.